BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, October 11, 2024
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» KUS-121 shows therapeutic potential in models of atherosclerotic disease
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cardiovascular
KUS-121 shows therapeutic potential in models of atherosclerotic disease
Sep. 3, 2024
No Comments
The valosin-containing protein (VCP) modulator KUS-121 from Kyoto University is in phase II development as an intravitreal treatment for nonarteritic central retinal artery occlusion, but its efficacy in atherosclerosis is unknown.
BioWorld Science
Conferences
European Society of Cardiology
Cardiovascular